Oncology Imaging AI: From Experimental To Fast-Scaling Market.

(MENAFN- GlobeNewsWire - Nasdaq) Oncology imaging AI is rapidly scaling, driven by advancements in breast and lung screening, CT/MR staging, and RT planning. Key opportunities lie in consistent imaging decisions, quantification, and strategic partnerships, with North America leading in revenue and Asia-Pacific emerging as a fast-growth region.

Dublin, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The "World Market for Oncology Imaging AI, 2023-2032" has been added to ResearchAndMarkets's offering.

Oncology is at the forefront of advancements in medical imaging AI, becoming increasingly integral within breast and lung screening programs and enhancing complex CT/MRI staging and PET-based theranostics, pushing toward more efficient and standardized imaging decisions.

This report delves into the transformation, providing a comprehensive analysis of the World Market for Oncology Imaging AI from 2023 to 2032:

• Modality: CT, X-ray/DR (incl. DBT), MRI, PET/Nuclear, Ultrasound
• Tumor Site: Breast, Lung/Chest, Prostate, Colorectal, Liver, Neuro-oncology, and others
• Clinical Application & Pathway Stage: Ranging from Screening & Risk to Treatment Planning and Response
• Revenue Streams & Buyer Types: Including Hardware, Software, Services, Cloud/PPU for Cancer Centers, IDNs/AMCs, Community Providers, and Teleradiology

Beyond numbers, the report utilizes M, ARC-Index, GTM Growth-Maturity, and innovative Upgrade & Package Ladders to illustrate how different segments such as AI Software vendors and Imaging OEMs can capitalize on this evolving market.

The aim is to provide actionable insights for executives, detailing where Oncology Imaging AI is poised for scalability and identifying critical areas for partnership and evidence-led strategies over the next three to five years.

Market Snapshot

Oncology Imaging AI is rapidly evolving from test phases to a well-established market with opportunities expanding tenfold between 2023 and 2032, achieving a CAGR in the low 30s. North America leads currently but Asia-Pacific is the fastest growing area, anticipated to surpass Europe due to strides in screening initiatives and cloud deployments. Europe remains robust, driven by regulation adaptations.

Expenditure largely centers on CT, X-ray/DBT, and MRI in oncology workflows, with PET/Nuclear and Ultrasound presenting smaller niche opportunities tied to theranostics and advanced interventional techniques. The value distribution also shifts along the clinical pathway, with increasing investment in screening, treatment planning, and response evaluation.

This report quantifies the Oncology Imaging AI landscape across modalities, tumor sites, applications, stages, revenue streams, and usage settings. It offers a directional overview for prospective buyers, with detailed metrics available in the full report.

What's Covered

• Global Market Sizing & Forecast (2023-2032): An in-depth growth outlook with scenario commentary and pivotal market moments.
• Granular Segmentation of Value Pools: Detailed analysis by modality, tumor site, clinical application, and more.
• Regional & Country Perspectives: Insights into major global regions, with a spotlight on fast-growth countries and regulatory environments.
• Clinical & Technology Trends: Comprehensive coverage of AI deployment across various oncology stages.
• Regulatory, Reimbursement, and Evidence Landscape (ARC): Review of approvals and clinical validations.
• Competitive Landscape by Cluster: Analysis of competitive dynamics across key market players.
• GTM & Packaging Strategies: Insights into commercialization strategies and expansion implications.
• Strategic Implications & Scenarios: Projections on future market evolution and competition within regionals.

Geographical Coverage

• North America (US, Canada)
• Europe (Germany, France, UK, Italy, Rest of Europe)
• Asia Pacific (China, Japan, India, Rest of Asia-Pacific)
• Latin America
• Middle East & Africa

Market Segmentation

• By Modality (CT, X-ray/DR, MRI, PET/Nuclear, Ultrasound)
• By Geographic Region
• By Tumor Site (Breast, Lung/Chest, Prostate, etc.)
• By Clinical Application (Detection/Triage, Segmentation, etc.)
• By Pathway Stage (Screening, Diagnosis, etc.)
• By End-Use Organization (Cancer Centers, Community Hospitals, etc.)
• By Revenue Stream (Hardware, Software, etc.)
• By AI Technology (Detection, Radiomics, etc.)

Key Topics Covered

• Global Market Sizing & Forecast (2023-2032)
• Segmentation of Value Pools
• Regional & Country Perspectives
• Clinical & Technology Trends
• Regulatory & Evidence Landscape (ARC)
• Competitive Landscape by Cluster
• GTM & Packaging Strategies
• Strategic Scenarios

Companies Featured

• 5C Network
• Accuray
• Aidoc
• AIQ Solutions
• Bracco
• Brainlab
• Canon Medical
• CARPL
• deepc (deepcOS)
• DocPanel
• Elekta
• Everlight Radiology
• Ferrum Health
• Fujifilm Healthcare
• GE HealthCare
• Guerbet
• Hologic
• Incepto
• Koios Medical
• Lantheus / EXINI (aPROMISE / PYLARIFY AI)
• Limbus AI
• Lunit
• Median Technologies
• MIM Software
• Mirada Medical
• MVision AI
• Nuance Precision Imaging Network (PIN)
• Philips Healthcare
• Quibim;
• QView Medical
• RadNet / DeepHealth
• RaySearch Laboratories
• Riverain Technologies
• Samsung Healthcare
• ScreenPoint Medical (Transpara)
• Siemens Healthineers
• Teleradiology Solutions
• Tempus (Arterys)
• Therapixel (MammoScreen)
• Unilabs / Telemedicine Clinic (TMC)
• United Imaging
• Vara
• vRad

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN17122025004107003653ID1110492059